NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

LUCD

Lucid Diagnostics Inc

Jul 03 • 04:00PM ET

1.03

Dollar change -0.02
Percentage change -1.90	%

Healthcare • Medical Devices • USA • NASD

Peers: GH EXAS FLGT NTRA MYGN QTRX CDNA CSTL BNR VCYT

| Held by: VTI IWM VXF IWN IWO IWC RSSL UWM URTY ITWO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.20	Insider Own	62.71%	Shs Outstand	84.37M	Perf Week	-13.45%
Market Cap	111.44M	Forward P/E	-	EPS next Y	-0.33	Insider Trans	0.52%	Shs Float	40.34M	Perf Month	-18.25%
Enterprise Value	175.89M	PEG	-	EPS next Q	-0.11	Inst Own	9.86%	Short Float	4.11%	Perf Quarter	-29.93%
Income	-70.94M	P/S	26.72	EPS this Y	31.90%	Inst Trans	127.50%	Short Ratio	1.20	Perf Half Y	28.73%
Sales	4.17M	P/B	-	EPS next Y	38.66%	ROA	-190.69%	Short Interest	1.66M	Perf YTD	25.81%
Book/sh	-0.71	P/C	4.42	EPS next 5Y	37.27%	ROE	-1897.35%	52W High	1.80 -42.78%	Perf Year	30.54%
Cash/sh	0.23	P/FCF	-	EPS past 3/5Y	-9.29% -54.43%	ROIC	-	52W Low	0.72 43.04%	Perf 3Y	-53.60%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	105.61% -	Gross Margin	-88.86%	Volatility	6.90% 6.13%	Perf 5Y	-
Dividend TTM	-	EV/Sales	42.18	EPS Y/Y TTM	5.87%	Oper. Margin	-1144.21%	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.72	Sales Y/Y TTM	39.89%	Profit Margin	-1699.86%	RSI (14)	29.99	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.75	EPS Q/Q	-30.13%	SMA20	-14.95%	Beta	1.23	Target Price	3.79
Payout	-	Debt/Eq	-	Sales Q/Q	-17.28%	SMA50	-18.34%	Rel Volume	0.84	Prev Close	1.05
Employees	72	LT Debt/Eq	-	Earnings	May 14 BMO	SMA200	-6.61%	Avg Volume	1.38M	Price	1.03
IPO	Oct 14, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-8.11% -35.34%	Trades		Volume	1,160,828	Change	-1.90%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-27-21	Initiated	Ascendiant Capital Markets	Buy	$16
Nov-08-21	Initiated	Needham	Buy	$17
Nov-08-21	Initiated	Cantor Fitzgerald	Overweight	$21
Nov-08-21	Initiated	BTIG Research	Buy	$14

Jun-18-25 12:01PM	Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test (PR Newswire)
May-27-25 07:31AM	Lucid Diagnostics to Join Russell 2000 and Russell 3000 Indexes (PR Newswire)
May-15-25 08:01AM	PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results (PR Newswire)
03:12AM	Lucid Diagnostics Inc (LUCD) Q1 2025 Earnings Call Highlights: Strategic Growth Amid Revenue ... (GuruFocus.com)
May-14-25 09:15AM	Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +7.56%
08:01AM	Loading…
08:01AM	Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results (PR Newswire)
May-13-25 08:15AM	908 Devices Inc. (MASS) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +8.18%
May-12-25 05:15PM	Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-07-25 10:00AM	Will Lucid Diagnostics Inc. (LUCD) Report Negative Earnings Next Week? What You Should Know (Zacks)
May-05-25 08:10AM	IRadimed (IRMD) Lags Q1 Earnings Estimates (Zacks)
May-01-25 08:31AM	PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025 (PR Newswire)
Apr-30-25 08:31AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025 (PR Newswire)
Apr-24-25 08:01AM	NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard Esophageal DNA Test in Patients Without Symptomatic GERD (PR Newswire)
Apr-21-25 05:01PM	Lucid Diagnostics Inc (LUCD) Q4 2024 Earnings Call Highlights: Record Test Volumes and ... (GuruFocus.com) +6.67%
Apr-11-25 09:23AM	Lucid Diagnostics Announces Closing of Public Offering of Common Stock (PR Newswire) -6.40%
07:24PM	Loading…
Apr-09-25 07:24PM	Lucid Diagnostics Announces Pricing of Public Offering of Common Stock (PR Newswire) -24.24%
04:01PM	Lucid Diagnostics Announces Proposed Public Offering of Common Stock (PR Newswire)
Apr-03-25 09:00AM	Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-27-25 08:01AM	Lucid Diagnostics Launches 'Embrace the Future' Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology (PR Newswire)
Mar-26-25 03:01AM	PAVmed Inc (PAVM) Q4 2024 Earnings Call Highlights: Strategic Growth and Financial Stability (GuruFocus.com)
Mar-25-25 11:15PM	Q4 2024 PAVmed Inc Earnings Call (Thomson Reuters StreetEvents)
08:01AM	PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Mar-24-25 12:17PM	Lucid Diagnostics Inc. (LUCD) Q4 2024 Earnings Call Transcript (SeekingAlpha)
09:10AM	Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:01AM	Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Mar-21-25 10:38PM	Lucid Diagnostics Inc (LUCD) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Mar-20-25 08:31AM	Lucid Diagnostics Announces Updated National Comprehensive Cancer Network (NCCN) Guidelines Now Include Esophageal Precancer Screening (PR Newswire)
Mar-18-25 08:31AM	Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard Esophageal Precancer Testing Accepted for Peer-Reviewed Publication (PR Newswire)
Mar-13-25 07:36AM	Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard Esophageal DNA Test (PR Newswire)
Mar-10-25 09:01AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025 (PR Newswire) -14.39%
04:45PM	Loading…
Mar-05-25 04:45PM	Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering (PR Newswire)
Mar-04-25 08:25AM	Lucid Diagnostics Announces $15.3 Million Registered Direct Offering (PR Newswire)
Feb-27-25 08:31AM	Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard in At-Risk Patients without Symptomatic GERD (PR Newswire) +5.26%
Feb-25-25 08:31AM	Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Feb-20-25 08:31AM	Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health (PR Newswire) -6.29%
Feb-18-25 08:30AM	PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement (PR Newswire) +8.90%
Feb-06-25 08:57AM	Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (PR Newswire)
Jan-13-25 07:56AM	Lucid Diagnostics Announces Record Quarterly EsoGuard Test Volume (PR Newswire)
Dec-23-24 08:01AM	Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule (PR Newswire)
Dec-19-24 08:01AM	Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters (PR Newswire)
Dec-11-24 08:01AM	Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard Esophageal DNA Test Accepted for Peer-Reviewed Publication (PR Newswire)
Dec-03-24 08:01AM	Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones (PR Newswire)
Nov-20-24 07:56AM	Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard Esophageal DNA Test (PR Newswire)
Nov-18-24 08:15AM	Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (PR Newswire)
Nov-15-24 06:23AM	Q3 2024 PAVmed Inc Earnings Call (Thomson Reuters StreetEvents)
02:09AM	PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring (GuruFocus.com)
Nov-14-24 08:01AM	PAVmed Provides Business Update and Third Quarter 2024 Financial Results (PR Newswire)
02:09AM	Lucid Diagnostics Inc (LUCD) Q3 2024 Earnings Call Highlights: Record Revenue Growth Amid ... (GuruFocus.com)
Nov-13-24 08:01AM	Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results (PR Newswire)
Nov-07-24 08:01AM	Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing Accepted for Peer-Reviewed Publication (PR Newswire) +5.95%
Nov-05-24 08:01AM	Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers (PR Newswire)
Oct-31-24 08:31AM	PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024 (PR Newswire)
Oct-30-24 08:31AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024 (PR Newswire)
Oct-15-24 07:51AM	Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test (PR Newswire)
07:30AM	Castle Biosciences price target raised to $40 from $35 at BTIG (TipRanks)
Oct-09-24 08:01AM	Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit (PR Newswire)
Oct-08-24 07:49AM	Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024 (PR Newswire)
Oct-01-24 08:01AM	Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players (PR Newswire)
Sep-24-24 08:01AM	American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test (PR Newswire)
Sep-16-24 04:30PM	PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements (PR Newswire)
Sep-10-24 07:56AM	Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress (PR Newswire)
Sep-03-24 07:51AM	Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health (PR Newswire)
Aug-20-24 08:16AM	Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard for Early Detection of Esophageal Precancer and Cancer (PR Newswire)
Aug-14-24 02:28AM	Q2 2024 PAVmed Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-13-24 08:16AM	The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard to Enhance Early Detection of Esophageal Cancer (PR Newswire)
08:01AM	PAVmed Provides Business Update and Second Quarter 2024 Financial Results (PR Newswire)
Aug-12-24 08:07AM	Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results (PR Newswire) +6.33%
Aug-08-24 08:31AM	Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard #CheckYourFoodTube Precancer Testing Event (PR Newswire)
Aug-06-24 08:15AM	Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard Esophageal Precancer Testing (PR Newswire)
Aug-05-24 08:15AM	Lucid Diagnostics to Participate in Upcoming Investor Conferences (PR Newswire)
Jul-30-24 08:15AM	PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024 (PR Newswire)
Jul-29-24 08:15AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024 (PR Newswire)
06:00AM	3 Hypergrowth Stocks That Speculators Should Keep Tabs On (InvestorPlace)
Jul-23-24 08:01AM	Lucid Diagnostics Announces Record Quarterly EsoGuard Test Volume (PR Newswire)
Jul-11-24 08:31AM	Lucid Diagnostics Launches New Corporate Website (PR Newswire)
Jul-04-24 11:29AM	Lucid Diagnostics (LUCD) Reports Positive ESOGUARD BE-1 Data (Zacks)
Jul-02-24 07:55AM	Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing in a Screening Population (PR Newswire)
Jun-12-24 08:05AM	4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard Esophageal Precancer Testing (PR Newswire)
May-20-24 06:00AM	Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024 (InvestorPlace)
May-15-24 02:34AM	Q1 2024 PAVmed Inc Earnings Call (Thomson Reuters StreetEvents)
May-14-24 08:21AM	Lucid Diagnostics Inc. (NASDAQ:LUCD) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:01AM	Lucid Diagnostics Inc (LUCD) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and ... (GuruFocus.com)
May-13-24 08:43PM	PAVmed Provides Business Update and First Quarter 2024 Financial Results (PR Newswire)
12:53PM	LUCD Stock Earnings: Lucid Diagnostics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:00AM	Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results (PR Newswire)
May-09-24 07:49AM	Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall (PR Newswire)
May-07-24 07:39AM	Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors (PR Newswire)
May-02-24 08:35AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024 (PR Newswire) +8.11%
07:49AM	Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing (PR Newswire)
Apr-29-24 08:47AM	Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month (PR Newswire) +9.90%
Apr-19-24 06:00AM	3 Penny Stocks That Could Make a Big Comeback by the End of Q2 (InvestorPlace)
Apr-08-24 08:30AM	Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-28-24 09:47AM	PAVmed Inc. (NASDAQ:PAVM) Q4 2023 Earnings Call Transcript (Insider Monkey) -18.19%
02:00AM	Q4 2023 PAVmed Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-27-24 12:35PM	Lucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2023 Earnings Call Transcript (Insider Monkey)
12:14AM	Q4 2023 Lucid Diagnostics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-26-24 07:32PM	PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results (PR Newswire) -6.60%
Mar-25-24 10:53PM	LUCD Stock Earnings: Lucid Diagnostics Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:30PM	Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Mar-21-24 09:30AM	Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard Esophageal Precancer Testing in a Screening Population (PR Newswire)

Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company was founded by Lishan Aklog on May 8, 2018 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Matheis Dennis	Director	May 20 '25	Buy	1.29	187,098	242,292	187,098	May 22 04:45 PM
Matheis Dennis	Director	May 21 '25	Buy	1.32	129,684	171,520	316,782	May 22 04:45 PM
Matheis Dennis	Director	May 22 '25	Buy	1.32	33,218	43,795	350,000	May 22 04:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LUCD

Lucid Diagnostics Inc

Upgrade your FINVIZ experience